PURPOSE: To assess the efficacy and safety of intraprostatic injection of two botulinum neurotoxin type A (BoNT-A) doses for the treatment of benign prostatic hyperplasia (BPH).
MATERIALS AND METHODS: Men with symptomatic BPH who failed medical treatment were randomized to receive 100 U or 200 U of BoNT-A into the prostate. The International Prostatic Symptom Score (IPSS), maximum flow rate (Qmax), post-void residual volume (PVR), PSA levels and prostate volume before injection and after 3 and 6 months were evaluated. Adverse events were compared between the groups.
RESULTS: Thirty four patients were evaluated, including 17 in the BoNT-A 100 U group and 17 in the BoNT-A 200 U group. Baseline characteristics were similar in both groups. Both doses produced significant improvements in IPSS, Qmax and PVR after 3 and 6 months and both doses promoted comparable effects. Prostate volume was affected by 200 U BoNT-A injection only after 6 months of treatment. PSA levels were significantly affected in the 100 U group only after 6 months of treatment. In the 200 U group, PSA levels were significantly decreased after 3 and 6 months. The complication rate was similar in both groups.
CONCLUSIONS: Efficacy and safety of both BoNT-A doses are similar for BPH treatment in the short term followup.
Written by:
Arnouk R, Suzuki Bellucci CH, Benatuil Stull R, de Bessa J Jr, Malave CA, Mendes Gomes C. Are you the author?
Department of Urology, Dr. Carlos Arvelo Military Hospital, 1060 Caracas, Miranda, Venezuela.
Reference: ScientificWorldJournal. 2012;2012:463574.
doi: 10.1100/2012/463574
PubMed Abstract
PMID: 22997495
